A clinical trial is starting in Danbury for a drug that doctors hope will slow disease progression in individuals with early-stage Parkinson’s.  Nuvance Health is enrolling participants in a clinical trial to evaluate the safety and efficacy of the investigational drug UCB0599.  Associated Neurologists on Sand Pit Road is the only site in Connecticut conducting the Orchestra clinical trial, an 18-month study.  Individuals diagnosed with Parkinson's within the last two years in overall good health who have not received medication for PD-associated motor symptoms may be eligible for the study.  Approximately 60-thousand people are diagnosed with Parkinson’s disease each year in the United States and 10 million people are living with it worldwide.  It's the second most common neurodegenerative disease after Alzheimer’s.  Symptoms of the progressive movement disorder include trembling of hands, arms, legs, jaw and face and poor balance and coordination. As symptoms worsen, individuals may have difficulty chewing, swallowing or speaking, talking or walking.  Individuals who think they may be eligible or physicians referring their patients to the clinical trial can call (203) 739-4551 or email OfficeofClinicalTrials@NuvanceHealth.org.